Explore
You don't have any items in your cart yet.
Please change the country on your profile in order to switch to another country store.
Through our reach and resources
Optimize cell expansion and cryopreservation to maximize cell processing throughput
Improve efficiency in 2 key cell therapy workflow steps
Manual, open processing is not ideal for commercial production of chimeric antigen receptor (CAR T) cells. This study describes development of a closed and semi-automated process that can be adapted for GMP compliance and CAR T developers’ needs.
A robust workflow that can be adapted for cGMP compliance in commercial production. Achieves 1 × 1010 expanded T cells in 8 days.
Development of a scalable process to produce high-yield lentiviral vector batches using stable, suspension-based production methods.
CBMG accelerates cell therapy manufacturing with Cytiva’s start-to-finish FlexFactory for cellular therapies.
Customer study shows reproducible cord blood freezing without liquid nitrogen.
This study was designed to answer the question: When is it safe to transfer cell samples from a controlled-rate freezer to liquid nitrogen storage?
A proof-of-concept study that demonstrates the controlled cooling of large volume biological samples with high and consistent post-thaw recovery. An alternative solution to cryopreserving with liquid nitrogen.
Expand your knowledge on perfusion, our rocking technology and more by reading through our latest papers and posters.
Cooling protocol and proof-of-concept study for the cryopreservation of large-volume biological samples in cryovials. Achieve high and consistent post-thaw recovery of up to 50 mL in this liquid nitrogen-free cell freezing method.
SpinOculation C-Pro protocol software offers a closed, automated solution for gene transfer by lentiviral transduction in CAR-T cell therapy processing.
Switching to a liquid nitrogen-free controlled-rate freezer can reduce carbon emissions by 87% over 10 yr and decrease operating costs by up to 97%. Read our study to see how you could minimize the environmental impact of your cryopreservation.
Two cell therapy experts provide practical advice on when and how to start thinking about compliance with good manufacturing practices (GMP).
How to prepare for the future of viral vector production to meet the demand generated by gene-modified cell therapies and gene therapies. Based on interview with Phil Vanek.
How does a power interruption during cooling affect post-thaw cell viability? This study demonstrates minimal effect of power outages and interrupted cooling during cryopreservation when using a VIA Freeze controlled-rate freezer.
This study shows comparable results when freezing cells with or without a rapid-cooling nucleation step.
Upstream lentiviral vector process with stable producer cell line that can be adapted for commercial manufacturing. Scales linearly from 5 to 28 L in Xcellerex bioreactors yielding ≥ 1010 TU/L of LV-GFP.
Workflow for NK cell production from apheresis units. Isolation, xeno-free expansion, harvest, and cryopreservation amenable to GMP manufacturing.
Customer case study describes a robust upstream process and downstream process for oncolytic adenovirus production. Purity of final samples meets regulatory requirements.
A new software platform is designed to simplify cell therapy processes. It offers many features and a single digital space to support both consistent production and compliance with regulations such as cGMP.
Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Here two industry experts provide practical advice on strategies to meet supply chain challenges.
For cell and gene therapies, the supply chain and logistics are critical. Collaboration is the key to solving data management and process variability challenges.
Read about this benchmarking study and benefits of dry thawing technology.
Large-scale AAV production processes are needed to industrialize gene therapies. This customer case study describes microcarrier culture in a 1 L bioreactor.
TILs are showing promise as cancer treatments for solid tumors. Learn what they are and how they differ from CAR T cells.
By using automation to minimize human interaction and time and resource requirements, you can increase your product’s speed to market and mitigate many of the risks and costs associated with commercialization.
Calculating working volumes for your Percoll solutions is now easier. Download it to your preferred device or use the web app.
Visit our collection of videos to learn more about Cytiva cell therapy technologies.
